A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-cell Prolymphocytic Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03873493|
Recruitment Status : Recruiting
First Posted : March 13, 2019
Last Update Posted : November 6, 2019
A study to evaluate the safety and efficacy of venetoclax plus ibrutinib for participants with T-cell Prolymphocytic Leukemia (T-PLL) and follows a 2-stage design as follows:
Stage 1: Enroll up to 14 participants and move to Stage 2 if 4 or more subjects meet protocol-specified response criteria. Response assessment will be performed on a continued basis until all 14 participants have enrolled into Stage 1 and have completed the Week 24 disease assessment.
Stage 2: Enroll up to an additional 23 participants with previously untreated or relapsed or refractory T-PLL.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia T-cell Prolymphocytic Leukemia (T-PLL) Cancer||Drug: Venetoclax Drug: Ibrutinib||Phase 2|
Expanded Access : An investigational treatment associated with this study is available outside the clinical trial. More info ...
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||37 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia|
|Actual Study Start Date :||November 1, 2019|
|Estimated Primary Completion Date :||September 21, 2022|
|Estimated Study Completion Date :||January 3, 2024|
Experimental: Venetoclax + Ibrutinib
Venetoclax 400 mg, potentially up to 600 mg, orally once daily (QD) plus Ibrutinib 420 mg dosed orally QD.
Other Name: Imbruvica
- Overall Response Rate (ORR) [ Time Frame: Up to approximately 2 years ]ORR is defined as the percentage of participants achieving complete remission (CR), CR with incomplete bone marrow recovery (CRi), or partial response (PR) as their best response (per investigator assessment).
- Progression-Free Survival (PFS) [ Time Frame: Up to approximately 2 years ]PFS is defined as the time from the participant's first dose of study drug to the date of documented disease progression, or death.
- Time to Progression (TTP) [ Time Frame: Up to approximately 2 years ]TPP is defined as the time from the date of the participant's first dose of study drug to the date of documented disease progression; does not include deaths.
- Duration of Response (DOR) [ Time Frame: Up to approximately 2 years ]DOR defined as the time from the date of first response (CR, CRi, or PR) to the date of disease progression.
- Overall Survival (OS) Rate [ Time Frame: Up to approximately 2 years ]OS is defined as the time from the date of the participant's first dose of study drug to to the date of death from any cause.
- Number of Participants Reaching Autologous or Allogeneic Transplantation [ Time Frame: Up to approximately 2 years ]Number of participants reaching autologous or allogeneic transplantation.
- Event-free Survival (EFS) [ Time Frame: Up to approximately 2 years ]EFS is defined as time from participant's first dose of study drug to disease progression, death, or discontinuation of treatment for any reason.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03873493
|Contact: ABBVIE CALL CENTERfirstname.lastname@example.org|
|United States, Massachusetts|
|Dana-Farber Cancer Institute /ID# 207728||Not yet recruiting|
|Boston, Massachusetts, United States, 02215|
|United States, Minnesota|
|Mayo Clinic - Rochester /ID# 207692||Not yet recruiting|
|Rochester, Minnesota, United States, 55905-0001|
|United States, Texas|
|University of Texas MD Anderson Cancer Center /ID# 207746||Not yet recruiting|
|Houston, Texas, United States, 77030|
|Peter MacCallum Cancer Ctr /ID# 209554||Recruiting|
|Melbourne, Victoria, Australia, 3000|
|Medizinische Universität Wien /ID# 208497||Not yet recruiting|
|Vienna, Wien, Austria, 1090|
|Helsinki University Hospital /ID# 208108||Not yet recruiting|
|Helsinki, Uusimaa, Finland, 00290|
|Centre Hospitalier Lyon Sud /ID# 208731||Not yet recruiting|
|Pierre Benite CEDEX, Auvergne-Rhone-Alpes, France, 69495|
|CHRU Lille - Hôpital Claude Huriez /ID# 208726||Not yet recruiting|
|Lille CEDEX, Hauts-de-France, France, 59045|
|Hopital Pitie Salpetriere /ID# 208730||Not yet recruiting|
|Paris, France, 75651|
|University Hospital Cologne /ID# 208834||Not yet recruiting|
|Cologne, Germany, 50937|
|Azienda Policlinico Umberto I /ID# 212254||Not yet recruiting|
|Roma, Italy, 00161|
|Azienda Sanitaria Universitaria Integrata di Trieste Ospedale Maggiore /ID# 211487||Not yet recruiting|
|Trieste, Italy, 34129|
|Maxima Medisch Centrum /ID# 207989||Not yet recruiting|
|Eindhoven, Netherlands, 5600 PD|
|Universitair Medisch Centrum Groningen /ID# 207990||Not yet recruiting|
|Groningen, Netherlands, 9713 GZ|
|St. James University Hospital /ID# 211265||Not yet recruiting|
|Leeds, United Kingdom, LS9 7TF|
|Royal Marsden Hospital /ID# 211263||Not yet recruiting|
|London, United Kingdom, SW3 6JJ|
|Oxford Univ Hosp NHS Trust /ID# 211264||Not yet recruiting|
|Oxford, United Kingdom, OX3 7LE|
|Study Director:||AbbVie Inc.||AbbVie|